The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First look at the baseline characteristics of participants in IRONMAN, the international registry for men with advanced prostate cancer.
 
Lorelei A Mucci
Employment - Convergent Therapeutics (I)
Leadership - Context Therapeutics (I); Genentech/Roche (I); Merck (I)
Stock and Other Ownership Interests - Context Therapeutics (I); Convergent Therapeutics; Druggablity Technologies (I); Placon (I); Seer (I); Tarveda Therapeutics (I)
Consulting or Advisory Role - Bavarian Nordic (I); Bayer; GE Healthcare (I); Janssen Oncology (I); New England Research Institutes (I); OncoCellMDx (I); Progenity (I); Sanofi (I)
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
 
Jake Vinson
No Relationships to Disclose
 
Travis A. Gerke
No Relationships to Disclose
 
Terry Hyslop
Consulting or Advisory Role - Abbvie
Travel, Accommodations, Expenses - Abbvie
 
Lauren Howard
Research Funding - Bayer (Inst); Diasorin (Inst); Ferring (Inst); LungLife AI (Inst); MDxHealth (Inst); Merck (Inst); Myriad Genetics (Inst); Sanofi (Inst)
 
Robert Dreicer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AVEO; Bayer; Exelixis; Genzyme; Gilead Sciences; Hengrui Pharmaceutical; Hinova Pharmaceuticals; Janssen Oncology; Merck; Pfizer; Tavanta Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Seagen (Inst)
 
Dana E. Rathkopf
Consulting or Advisory Role - AstraZeneca; Bayer; Genentech; Janssen; Myovant Sciences
Research Funding - AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Ferring (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Medivation (Inst); Millennium (Inst); Novartis (Inst); Phosplatin Therapeutics (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Kim N. Chi
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; POINT Biopharma; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Constellation Pharmaceuticals; Daiichi Sankyo; ESSA; Janssen; Merck; POINT Biopharma; Roche; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Expert Testimony - AstraZeneca; Novartis
 
Emilio Esteban
Travel, Accommodations, Expenses - Pfizer/EMD Serono; Pfizer/EMD Serono
 
Deborah Enting
Honoraria - Astellas Pharma
Consulting or Advisory Role - Bayer
Speakers' Bureau - Janssen Oncology
 
Anders Bjartell
Stock and Other Ownership Interests - Glactone Pharma; Lidds; WntResearch
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen-Cilag; Merck; Recordati; Sandoz
Speakers' Bureau - Astellas Pharma; Ipsen; Janssen-Cilag
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Ferring (Inst)
Travel, Accommodations, Expenses - Astellas Pharma
 
Scott T. Tagawa
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Dendreon; Endocyte; Genentech; Genomic Health; Gilead Sciences; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics
 
David M. Nanus
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Exelixis (Inst); immumedics (Inst); Janssen (Inst); Novartis (Inst); pfizer (Inst); Zenith Epigenetics (Inst)
 
Michael Ong
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; Merck; Pfizer
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Janssen; Merck; Pfizer/EMD Serono; Sanofi
Research Funding - AstraZeneca
 
Pedro C. Barata
Consulting or Advisory Role - AstraZeneca; AVEO; Bayer; BMS; Caris Life Sciences; Dendreon (Inst); Eisai; EMD Serono; Exelixis; Pfizer
Speakers' Bureau - Bayer (Inst); Caris Life Sciences (Inst); Pfizer/Astellas (Inst)
Research Funding - AVEO (Inst); Blue Earth Diagnostics (Inst); Merck (Inst); Pfizer (Inst)
 
Sebastien J. Hotte
Honoraria - Astellas Scientific and Medical Affairs Inc; Bayer; Eisai; Ipsen; Janssen Oncology; Merck
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Pfizer; Seagen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SignalChem (Inst)
Travel, Accommodations, Expenses - Eisai
 
Marie Grant
No Relationships to Disclose
 
Paul Villanti
No Relationships to Disclose
 
Philip W. Kantoff
Employment - Convergent Therapeutics
Leadership - Context Therapeutics; Convergent Therapeutics; XLink
Stock and Other Ownership Interests - Cogent Biosciences; Context Therapeutics; Druggablity Technologies; Mirati Therapeutics; Placon; PrognomIQ; Seer; SynDevRx; XLink
Consulting or Advisory Role - Anji Pharma; Candel Therapeutics; Context Therapeutics; Druggablity Technologies; Genentech/Roche; Janssen; Merck; OncoCellMDX; Progenity; PrognomIQ; Seer; SynDevRx; Tarveda Therapeutics; Veru; XLink
Patents, Royalties, Other Intellectual Property - Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality; Composition and Methods for Screening and Diagnosis of Prostate Cancer; Drug Combinations to Treat Cancer; Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality; Methods and Kits for Determining Sensitivity to Cancer Treatment; Methods for Predicting Likelihood of Responding to Treatment; Predicting and Treating Prostate Cancer; Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent); Up-to-Date Royalties; Wolters Kluwer Royalties
Other Relationship - Bayer (I)
 
Daniel J. George
Leadership - Capio BioSciences
Honoraria - Acceleron Pharma; American Association for Cancer Research; Axess Oncology; Bayer; EMD Serono; Exelixis; Janssen Oncology; Millennium Medical Publishing; OncLive; Pfizer; Sanofi; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Myovant Sciences; Pfizer; Physicans' Education Resource; Propella Therapeutics; RevHealth; Sanofi; Xcures
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Dendreon (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi; UroToday